A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension

The purpose of this study to evaluate the drug Tadalafil and how much of the study drug is in the blood after dosing in children with pulmonary arterial hypertension (PAH) and to establish the correct dose for further clinical research.

Trial Summary

Age Range
6 months - 17 years
Conditions the trial is for
Pulmonary Arterial Hypertension
What the trial is testing?
Tadalafil
Could I receive a Placebo?
No
Enrollment Goal
20
Trial Dates
Jul 17, 2012 - Apr 3, 2019
How long will I be in the trial?
Your participation could last approximately 10 weeks with the opportunity to continue taking Tadalafil for at least 2 years.
Trial Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.